Coya Therapeutics (COYA) Accumulated Expenses (2021 - 2026)
Coya Therapeutics (COYA) posted Accumulated Expenses of $352347.0 for Q1 2026, down 90.25% sequentially from $3.6 million in Q4 2025, and up 12.11% YoY from $314273.0 in Q1 2025.
Coya Therapeutics (COYA) Accumulated Expenses (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Accumulated Expenses for 6 years, with the latest figure at $352347.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 12.11% year-over-year to $352347.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $352347.0 (up 12.11% YoY) and the FY2025 annual result came in at $3.6 million, up 160.29% from the prior year.
- Accumulated Expenses retreated to $352347.0 in Q1 2026 per COYA's latest filing, from $3.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $3.6 million in Q4 2025 and troughed at $314273.0 in Q1 2025.
- A 5-year average of $1.2 million and a median of $974546.5 in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 590.6% in 2022, then slumped 84.61% in 2025.
- Over 5 years, Accumulated Expenses stood at $2.0 million in 2022, then tumbled by 46.16% to $1.1 million in 2023, then gained by 28.37% to $1.4 million in 2024, then soared by 160.29% to $3.6 million in 2025, then tumbled by 90.25% to $352347.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $352347.0, $3.6 million, and $945840.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.19 Mn |
| Mar 31, 2026 | 352,347.00 |
| Dec 31, 2025 | 3.61 Mn |
| Sep 30, 2025 | 945,840.00 |
| Jun 30, 2025 | 591,464.00 |
| Mar 31, 2025 | 314,273.00 |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | 546,396.00 |
| Jun 30, 2023 | 415,514.00 |
| Mar 31, 2023 | 724,687.00 |
| Dec 31, 2022 | 2.01 Mn |
| Dec 31, 2021 | 290,816.00 |